These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39031351)

  • 1. Evaluation of SARS-Cov-2 neutralizing antibody among Sinopharm Vero Cell (BBIBP-CorV) vaccinated medical students.
    Khadka S; Regmi SM; Subedi N; Poudel A; Bhandari DR; Karn M; Pradhan S; Shrestha P
    Hum Antibodies; 2024 Jul; ():. PubMed ID: 39031351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
    Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
    Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.
    Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L
    Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
    Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
    Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
    Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
    Front Immunol; 2022; 13():967051. PubMed ID: 36159863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
    Erfanpoor S; Banihashemi SR; Mokhbaeralsafa L; Kalantari S; Es-Haghi A; Nofeli M; Rezaei Mokarram A; Sadeghi F; Hajimoradi M; Razaz SH; Taghdiri M; Lotfi M; Khorasani A; Ansarifar A; Masoumi S; Mohazzab A; Filsoof S; Mohseni V; Shahsavan M; Gharavi N; Setarehdan SA; Rabiee MH; Fallah Mehrabadi MH; Solaymani-Dodaran M
    BMC Med; 2024 Feb; 22(1):78. PubMed ID: 38378570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
    Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
    Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
    Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
    Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection.
    Jeewandara C; Aberathna IS; Dayarathna S; Nimasha T; Ranasinghe T; Jayamali J; Kamaladasa A; Karunanada M; Perera L; Ogg GS; Malavige GN
    PLoS One; 2022; 17(10):e0274845. PubMed ID: 36227884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
    Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA
    J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
    Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine.
    Farid E; Herrera-Uribe J; Stevenson NJ
    Front Immunol; 2022; 13():817597. PubMed ID: 35711448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
    Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.
    Hannawi S; Yan L; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Zhang M; Gao C; Chen Y; Gai W; Xie L
    EClinicalMedicine; 2023 Oct; 64():102195. PubMed ID: 37731938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
    Eybpoosh S; Biglari A; Sorouri R; Ashrafian F; Sadat Larijani M; Verez-Bencomo V; Toledo-Romani ME; Valenzuela Silva C; Salehi-Vaziri M; Dahmardeh S; Doroud D; Banifazl M; Mostafavi E; Bavand A; Ramezani A
    PLoS Pathog; 2023 Nov; 19(11):e1011744. PubMed ID: 37910480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
    Wen GP; Zhu M; Li LR; Li XJ; Ye HM; Zhou YL
    Front Immunol; 2023; 14():1099629. PubMed ID: 36817474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.